
Foot & Ankle
Ankle arthrodesis: rhPDGF-BB/TCP is an effective and safe alternative to autograft
J Bone Joint Surg Am. 2013 Jul 3;95(13):1184-92. doi: 10.2106/JBJS.K.01422Four hundred and thirty four patients in need of either an ankle or hindfoot arthrodesis were randomized to undergo the procedure using either the recombinant human (rh) PDGF-BB/TCP or autograft as bone fusion promoters to determine the non-inferiority of rhPDGF-BB/TCP. Results indicated that rhPDGF-BB/TCP proved to be non-inferior to autograft with respect to fusion rates, clinical union, radiographic union, pain, quality of life, and functional outcomes. Furthermore, rhPDGF-BB/TCP was equally, if not more, safe compared to autograft, with no significant differences between the two groups in terms of complications and adverse events.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.